Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREAS SCHMID

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962663377
CMS profile
761022
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$17,930.13

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Insmed, Inc. $17,930.13 21

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREAS SCHMID

NPI 1962663377 · CMS profile ID 761022

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962663377?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962663377?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962663377?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962663377?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $17,930.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $18.5411/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693333687 CMS
Insmed, Inc. $1,575.0011/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693333685 CMS
Insmed, Inc. $333.3308/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693330829 CMS
Insmed, Inc. $3.7508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693336381 CMS
Insmed, Inc. $24.0005/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693325973 CMS
Insmed, Inc. $6,400.0005/10/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693326055 CMS
Insmed, Inc. $40.0004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693323327 CMS
Insmed, Inc. $22.0004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693323329 CMS
Insmed, Inc. $50.0004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693323333 CMS
Insmed, Inc. $274.5004/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693323323 CMS
Insmed, Inc. $125.0004/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693323325 CMS
Insmed, Inc. $483.6504/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693329147 CMS
Insmed, Inc. $209.4604/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693330507 CMS
Insmed, Inc. $7,425.0004/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693320509 CMS
Insmed, Inc. $300.5604/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693326099 CMS
Insmed, Inc. $21.9904/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693325957 CMS
Insmed, Inc. $49.9904/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693325971 CMS
Insmed, Inc. $40.0004/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693326121 CMS
Insmed, Inc. $192.6604/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693326143 CMS
Insmed, Inc. $194.1804/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693326077 CMS
Insmed, Inc. $146.5203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693322343 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,930.13 21
PY2020 $7,244.44 9
PY2023 $1,117.56 9
PY2024 $15.37 1
PY2025 $72.62 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,654.12 9
PY2025 Principal investigator $330,468.44 168
PY2024 Principal investigator $383,470.04 191
PY2023 Principal investigator $688,078.36 235
PY2022 Principal investigator $419,549.56 143
PY2021 Principal investigator $95,534.58 57
PY2019 Principal investigator $7,217.27 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

143 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,051.51 12/31/2022 Non-covered Recipient Entity
UNIV OF KANSAS SW
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 914601861
Principal investigator 1 Insmed, Inc. $10,029.20 12/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143785
Principal investigator 1 Insmed, Inc. $26,744.40 12/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149279
Principal investigator 1 Insmed, Inc. $5.06 12/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149683
Principal investigator 1 Insmed, Inc. $16,715.30 11/16/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149199
Principal investigator 1 Insmed, Inc. $2.30 11/10/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144613
Principal investigator 1 Insmed, Inc. $1.11 11/10/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149619
Principal investigator 1 Insmed, Inc. $3.80 11/10/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149623
Principal investigator 1 Insmed, Inc. $0.92 10/24/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143991
Principal investigator 1 Insmed, Inc. $0.92 10/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908151911
Principal investigator 1 Insmed, Inc. $400.00 09/28/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144793
Principal investigator 1 Insmed, Inc. $53.40 09/28/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908151825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,153.00 09/27/2022 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 949197499
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143699
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143701
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143705
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143717
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143721
Principal investigator 1 Insmed, Inc. $8.73 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143753
Principal investigator 1 Insmed, Inc. $400.00 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143855
Principal investigator 1 Insmed, Inc. $5.85 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149233
Principal investigator 1 Insmed, Inc. $600.00 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149235
Principal investigator 1 Insmed, Inc. $133.50 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149239
Principal investigator 1 Insmed, Inc. $7.18 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149245
Principal investigator 1 Insmed, Inc. $22.00 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149259
Principal investigator 1 Insmed, Inc. $53.40 09/23/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149277
Principal investigator 1 Insmed, Inc. $16,715.30 09/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150299
Principal investigator 1 Insmed, Inc. $1.38 09/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908152359
Principal investigator 1 Insmed, Inc. $1.11 09/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144849
Principal investigator 1 Insmed, Inc. $2.53 09/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150301
Principal investigator 1 Insmed, Inc. $10,029.20 09/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150599
Principal investigator 1 Insmed, Inc. $133.50 08/31/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149401
Principal investigator 1 Insmed, Inc. $600.00 08/31/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908150195
Principal investigator 1 Insmed, Inc. $527.33 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143719
Principal investigator 1 Insmed, Inc. $2.53 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144771
Principal investigator 1 Insmed, Inc. $1.11 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144773
Principal investigator 1 Insmed, Inc. $444.56 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144791
Principal investigator 1 Insmed, Inc. $157.40 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144853
Principal investigator 1 Insmed, Inc. $400.00 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908145441
Principal investigator 1 Insmed, Inc. $26,744.40 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908145617
Principal investigator 1 Insmed, Inc. $2,127.32 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149267
Principal investigator 1 Insmed, Inc. $527.33 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149383
Principal investigator 1 Insmed, Inc. $1,515.69 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149393
Principal investigator 1 Insmed, Inc. $400.00 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149397
Principal investigator 1 Insmed, Inc. $1,424.38 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150325
Principal investigator 1 Insmed, Inc. $2.30 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150889
Principal investigator 1 Insmed, Inc. $444.56 07/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908152555
Principal investigator 1 Insmed, Inc. $1,671.53 07/21/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149097
Principal investigator 1 Insmed, Inc. $8,357.63 07/21/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149201
Principal investigator 1 Insmed, Inc. $0.44 07/21/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149289
Principal investigator 1 Insmed, Inc. $2.53 07/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144775
Principal investigator 1 Insmed, Inc. $16,715.30 07/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144851
Principal investigator 1 Insmed, Inc. $400.00 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143695
Principal investigator 1 Insmed, Inc. $8.73 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143723
Principal investigator 1 Insmed, Inc. $2,455.73 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143729
Principal investigator 1 Insmed, Inc. $665.00 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144589
Principal investigator 1 Insmed, Inc. $1,820.27 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144669
Principal investigator 1 Insmed, Inc. $400.00 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149241
Principal investigator 1 Insmed, Inc. $7.97 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149243
Principal investigator 1 Insmed, Inc. $133.50 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149253
Principal investigator 1 Insmed, Inc. $2,553.19 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149261
Principal investigator 1 Insmed, Inc. $3,210.01 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149265
Principal investigator 1 Insmed, Inc. $388.09 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149403
Principal investigator 1 Insmed, Inc. $388.09 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908150199
Principal investigator 1 Insmed, Inc. $2,110.44 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150323
Principal investigator 1 Insmed, Inc. $2,110.44 07/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150417
Principal investigator 1 Insmed, Inc. $1.11 07/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144777
Principal investigator 1 Insmed, Inc. $0.44 06/22/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144047
Principal investigator 1 Insmed, Inc. $22.00 06/07/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143727
Principal investigator 1 Insmed, Inc. $133.50 06/07/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143851
Principal investigator 1 Insmed, Inc. $5.03 06/07/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149257
Principal investigator 1 Insmed, Inc. $0.92 06/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150447
Principal investigator 1 Insmed, Inc. $1,653.87 05/19/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143759
Principal investigator 1 Insmed, Inc. $5.03 05/19/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149395
Principal investigator 1 Insmed, Inc. $2,110.44 05/19/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150365
Principal investigator 1 Insmed, Inc. $444.56 05/19/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908151599
Principal investigator 1 Insmed, Inc. $0.66 05/17/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908145611
Principal investigator 1 Insmed, Inc. $1.27 05/17/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150303
Principal investigator 1 Insmed, Inc. $150.00 05/15/2022 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908145613
Principal investigator 1 Insmed, Inc. $52,733.00 05/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143709
Principal investigator 1 Insmed, Inc. $5.84 05/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143811
Principal investigator 1 Insmed, Inc. $1,995.16 05/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143849
Principal investigator 1 Insmed, Inc. $133.50 05/12/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149399
Principal investigator 1 Insmed, Inc. $26,744.40 05/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144855
Principal investigator 1 Insmed, Inc. $0.66 05/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143671
Principal investigator 1 Insmed, Inc. $3.80 05/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144281
Principal investigator 1 Insmed, Inc. $1.38 05/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149205
Principal investigator 1 Insmed, Inc. $16,715.30 05/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149207
Principal investigator 1 Insmed, Inc. $0.92 05/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143743
Principal investigator 1 Insmed, Inc. $10,029.20 05/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144779
Principal investigator 1 Insmed, Inc. $5.06 05/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908144857
Principal investigator 1 Insmed, Inc. $1.84 05/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150305
Principal investigator 1 Insmed, Inc. $10,029.20 05/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150407
Principal investigator 1 Insmed, Inc. $0.88 05/02/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150491
Principal investigator 1 Insmed, Inc. $1,476.65 04/29/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143741
Principal investigator 1 Insmed, Inc. $2,670.00 04/29/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143853
Principal investigator 1 Insmed, Inc. $444.56 04/29/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144353
Principal investigator 1 Insmed, Inc. $133.50 04/29/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149857
Principal investigator 1 Insmed, Inc. $2,110.44 04/29/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150327
Principal investigator 1 Insmed, Inc. $3,343.05 04/06/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143841
Principal investigator 1 Insmed, Inc. $527.33 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143697
Principal investigator 1 Insmed, Inc. $21.97 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143703
Principal investigator 1 Insmed, Inc. $5.98 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143711
Principal investigator 1 Insmed, Inc. $21.47 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143715
Principal investigator 1 Insmed, Inc. $21.97 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144295
Principal investigator 1 Insmed, Inc. $22.49 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144305
Principal investigator 1 Insmed, Inc. $5.00 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144641
Principal investigator 1 Insmed, Inc. $1,875.01 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144689
Principal investigator 1 Insmed, Inc. $5.81 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149247
Principal investigator 1 Insmed, Inc. $21.97 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149385
Principal investigator 1 Insmed, Inc. $22.49 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149453
Principal investigator 1 Insmed, Inc. $133.50 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149679
Principal investigator 1 Insmed, Inc. $22.49 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908150201
Principal investigator 1 Insmed, Inc. $5.89 04/05/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908150203
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $9,134.16 03/28/2022 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 946866503
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $106.51 03/22/2022 Non-covered Recipient Entity
University Of Kansas Medical Center
CatC inhibitor Phase II in non CF bronchiectasis No dispute reported 06/30/2026 965112741
Principal investigator 1 Insmed, Inc. $33,430.50 03/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143675
Principal investigator 1 Insmed, Inc. $10,029.20 03/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144197
Principal investigator 1 Insmed, Inc. $388.09 03/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143839
Principal investigator 1 Insmed, Inc. $1,515.69 03/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143847
Principal investigator 1 Insmed, Inc. $5.03 03/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149147
Principal investigator 1 Insmed, Inc. $5.03 03/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149263
Principal investigator 1 Insmed, Inc. $157.40 03/04/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149345
Principal investigator 1 Insmed, Inc. $0.46 03/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143677
Principal investigator 1 Insmed, Inc. $2.53 03/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144095
Principal investigator 1 Insmed, Inc. $0.66 03/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149209
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,296.41 02/16/2022 Non-covered Recipient Entity
UNIV OF KANSAS SW
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 914593755
Principal investigator 1 Insmed, Inc. $600.00 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143707
Principal investigator 1 Insmed, Inc. $2,455.73 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143713
Principal investigator 1 Insmed, Inc. $600.00 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908144341
Principal investigator 1 Insmed, Inc. $133.50 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149237
Principal investigator 1 Insmed, Inc. $600.00 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149249
Principal investigator 1 Insmed, Inc. $133.50 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149769
Principal investigator 1 Insmed, Inc. $444.56 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149851
Principal investigator 1 Insmed, Inc. $527.33 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908149887
Principal investigator 1 Insmed, Inc. $444.56 02/11/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) No dispute reported 06/30/2026 908150321
Principal investigator 1 Insmed, Inc. $0.46 02/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143845
Principal investigator 1 Insmed, Inc. $1.27 02/03/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149987
Principal investigator 1 Insmed, Inc. $400.10 01/14/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908143775
Principal investigator 1 Insmed, Inc. $2,055.47 01/14/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149389
Principal investigator 1 Insmed, Inc. $1,653.87 01/14/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 908149873
Principal investigator 1 Insmed, Inc. $527.33 01/10/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908143725
Principal investigator 1 Insmed, Inc. $1,820.27 01/10/2022 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 908144665